pre-IPO PHARMA

COMPANY OVERVIEW

Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, without the immune system suppression seen with current therapies. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system to prevent the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1805 is a modified analogue of a key protein in immune function and is entering its second Phase 2 clinical trial for moderate-to-severe rheumatoid arthritis and a Phase 2 clinical trial for non-infectious uveitis. ‘1104 is a peptide derived from a natural immune-regulatory protein and is entering Phase 2 clinical development for patients with eosinophilic esophagitis (EoE) and a Phase 2 clinical trial for allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.


LOCATION

  • New Orleans, LA, USA
  • Cambridgeshire , , UK

  • THERAPEUTIC AREAS

  • Autoimmune Disease

  • WEBSITE

    https://revolobio.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    24haymarket metellus morningside


    PRESS RELEASES


    Jul 18, 2023

    Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis


    Jul 18, 2023

    Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis


    Jun 5, 2023

    Revolo Biotherapeutics Presents New Data for ‘1805 in Inflammatory Bowel Disease and Rheumatoid Arthritis at the 5th Treg Directed Therapies Summit


    May 22, 2023

    Revolo Biotherapeutics Presents New Preclinical Data for ‘1104 in Acute Respiratory Distress Syndrome Associated With Influenza Infection at the ATS 2023 International Conference


    May 10, 2023

    Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings


    For More Press Releases


    Google Analytics Alternative